Evaluating the effect of Agomelatine in patients with obstructive sleep apnea

Evaluating the effect of Agomelatine on polysomnography parameters in patients with obstructive sleep apnea

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20151227025726N26

Enrollment

Registered

2021-06-13

Start date

2021-07-02

Completion date

Unknown

Last updated

2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea. Obstructive sleep apnea (adult) (pediatric)

Interventions

Intervention 1: Intervention group: Patients in the intervention group, receive two 25 mg agomelatine tablets of Tadbir Kalay-e Jam pharmaceutical company one hour before bedtime, two nights before sl

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with age above 18 years old with obstructive sleep apnea that refer to the Sleep Clinic of Masih Daneshvari Hospital.

Exclusion criteria

Exclusion criteria: Pregnancy Breastfeeding Neurological disease (stroke, epilepsy, tumor, previously neurological manipulation) Use of stimulant drugs Allergy to Agomelatine or formulation components Having stage 2 or 3 of liver failure Ciprofloxacin consumption Fluvoxamine consumption

Design outcomes

Primary

Measure	Time frame
The assessment of polysomnography parameters. Timepoint: The assessment of polysomnography parameters 2 days after agomelatine consumption. Method of measurement: With measurement of recorded criteria in the polysomnography test response.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehnaz Gholizade Niari

Shahid Beheshti University of Medical Sciences

niazibehnaz89@yahoo.com+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026